

## Helsinn Therapeutics – Discontinuation of Truseltiq<sup>®</sup> (infigratinib)

- <u>Helsinn Therapeutics recently announced</u> the discontinuation of <u>Truseltiq (infigratinib)</u> because of difficulties in recruiting and enrolling study participants for the required confirmatory trial. The discontinuation is not due to safety or efficacy reasons.
- Helsinn Therapeutics will discontinue distribution of Truseltiq capsules in the first quarter of 2023 and is now ending all promotional and educational activities. Product will be available until March 31, 2023.
- Truseltiq is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
  - This indication was approved under accelerated approval based on overall response rate and duration of response.
- Helsinn Therapeutics strongly recommends against health care providers starting new patients on Truseltiq.

Product Description	NDC#
Truseltiq 50 mg capsules	72730-0506-01
Truseltiq 75 mg capsules	72730-0202-01
Truseltiq 100 mg capsules	72730-0111-01
Truseltiq 125 mg capsules	72730-0101-01

 Contact Helsinn Therapeutics Medical Information Department at 1-855-541-3495 for any questions.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.